There may be new hope for those suffering from nasal obstruction, congestion, and nasal polyps who have previously undergone a sinus surgery. Sinuva, an innovative technology, is designed to open in the sinus cavity and deliver anti-inflammatory medicine that treats nasal polyps.
Delivered into the sinus cavity through the nasal opening, Sinuva can be placed during a routine visit to your physician’s office using local or topical anesthesia and usually cannot be felt once it’s in place.
In the clinical studies, Sinuva was proven to shrink nasal polyps and reduce symptoms of nasal obstruction and congestion for up to 90 days. Patients who were treated with Sinuva reported reduced sinus obstruction and an improvement in their previously compromised sense of smell.
The corticosteroid-eluting implant was approved last November by the Food and Drug Administration (FDA) to treat nasal polyp disease in patients 18 years of age and older who have previously had ethmoid sinus surgery. This was based on data from the clinical studies of 400 patients.
Made from bio-absorbable polymers designed to soften over time, Sinuva may be expelled through forceful nose blowing as the implant softens and the polyps shrink. The implant can also be removed at 90 days or sooner at a physician’s discretion. Repeat administration of Sinuva has not been studied.
Minimal adverse reactions or side effects were observed or reported and included bronchitis, headache, nasopharyngitis, otitis media, presyncope, asthma, and epistaxis.
Sinuva is not indicated for those with hypersensitivity to corticosteroids and nasal ulcers and should not be used by anyone who is allergic to mometasone furoate or any of the implant’s ingredients.
Before receiving Sinuva, let your doctor know about any and all medical conditions but especially: nasal/sinus problems such as nasal ulcers or trauma, fungal, bacterial or viral infections, and any eye problems such as glaucoma or cataracts. If you think that you might be a candidate for Sinuva, schedule an appointment today.